CAS No. :	111406-87-2
Formula :	C₁₁H₁₂N₂O₂S
M.W :	236.29
SMILES Code :	CC(N(O)C(N)=O)C1=CC2=CC=CC=C2S1
Synonyms :	A 64077; Abbott 64077
MDL No. :	MFCD00866097
InChI Key :	MWLSOWXNZPKENC-UHFFFAOYSA-N
Pubchem ID :	60490

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H319-H351-H361
Precautionary Statements:	P305+P351+P338

HUVECs	1–50 µM	1 hour	Zileuton significantly inhibited VEGF-induced proliferation of HUVECs, as confirmed by MTT assay and BrdU incorporation assay.	Cells. 2019 Sep 30;8(10):1182.
Mouse peritoneal macrophages	1-100 µM	24 hours	Zileuton significantly reduced PGE2 and 6-keto PGF1α levels, with an IC50 of 5.79 µM.	Br J Pharmacol. 2010 Oct;161(3):555-70.
J774 macrophages	1-100 µM	24 hours	Zileuton significantly inhibited PGE2 production, with an IC50 of 1.94 µM.	Br J Pharmacol. 2010 Oct;161(3):555-70.
Human whole blood	1-100 µM	24 hours	Zileuton significantly inhibited COX-2-dependent PGE2 production, with an IC50 of 12.9 µM.	Br J Pharmacol. 2010 Oct;161(3):555-70.
BV-2 cells	5, 10, 15, 20 µM	24 hours	To investigate the effect of Zileuton on BV-2 cell viability, results showed that Zileuton at high concentrations (20 µM) could inhibit the over-proliferation of BV-2 cells.	Int J Mol Sci. 2022 Apr 28;23(9):4910.
Human dermal fibroblasts (HDFs)	0, 5, 10, 20 µM	24 hours	Zileuton treatment significantly reduced 5-LO and SASP levels and inhibited the expression of senescence markers.	Int J Mol Sci. 2022 Jul 29;23(15):8390.

Rats	Carrageenan-induced pleurisy	Intraperitoneal injection	10 mg/kg	Single dose, lasting 4 hours	Zileuton significantly reduced the levels of LTB4, PGE2, and 6-keto PGF1α in pleural exudates and attenuated the inflammatory response.	Br J Pharmacol. 2010 Oct;161(3):555-70.
SKH-1 mice	Radiation-induced cutaneous ulcer model	Topical application	200 μM	Daily until the day of euthanasia	Zileuton treatment significantly inhibited 5-LO expression and inflammatory cell infiltration, promoting the healing of radiation ulcers.	Int J Mol Sci. 2022 Jul 29;23(15):8390.
Sprague Dawley rats	Asthma model	Oral gavage	30 mg/kg	Once daily for 15 days	To evaluate gender differences in the pharmacokinetics of zileuton in a rat model. Results showed that female rats exhibited higher plasma concentrations of zileuton compared to male rats across all forms of zileuton (API, PM, and NfZ).	Int J Pharm X. 2024 May 4;7:100254
Wistar albino rats	PCOS model	Oral	5 mg/kg	Twice daily for 15 days	Zileuton significantly alleviated inflammation, apoptosis, and ferroptosis in the PCOS rat model, and improved oxidative stress and hormonal levels	Redox Rep. 2025 Dec;30(1):2445398
C57BL/6J mice	Matrigel plug model	Subcutaneous injection	50 µM	Once daily for 7 days	Zileuton significantly inhibited VEGF-induced angiogenesis in vivo, as confirmed by Matrigel plug assay and hemoglobin content measurement.	Cells. 2019 Sep 30;8(10):1182.
CD1 mice	Spinal cord injury model	Oral	50 mg/kg	1 hour and 6 hours after injury, daily for 10 days	To evaluate the effect of Zileuton on inflammation and tissue injury after spinal cord injury. Results showed that Zileuton significantly reduced spinal cord inflammation and tissue injury, and improved the recovery of motor function.	Br J Pharmacol. 2008 Feb;153(3):568-82

NCT00595114	-		Completed	-	United States, Massachusetts ... More >> Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Less <<
NCT00595114	-		Completed	-	-
NCT01125748	-		Completed	-	-
NCT00467831	Hermansky-Pudlak Syndrome (HPS... More >>) Pulmonary Fibrosis Oculocutaneous Albinism Platelet Storage Pool Deficiency Metabolic Disease Less <<	Phase 1 Phase 2	Terminated(insufficient enroll... More >>ment) Less <<	-	United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT01125748	Allergic Asthma	Phase 4	Completed	-	-
NCT00467831	-		Terminated(insufficient enroll... More >>ment) Less <<	-	-
NCT00723021	-		Completed	-	-
NCT01805687	Asthma	Phase 4	Completed	-	United States, Massachusetts ... More >> Northeast Medical Research Associates North Dartmouth, Massachusetts, United States, 02747 Less <<
NCT00723021	Asthma	Phase 2	Completed	-	United States, Maryland ... More >> Pfizer Investigational Site Baltimore, Maryland, United States, 21225 United States, Massachusetts Pfizer Investigational Site North Dartmouth, Massachusetts, United States, 02747 United States, Michigan Pfizer Investigational Site Kalamazoo, Michigan, United States, 49007 United States, Nebraska Pfizer Investigational Site Omaha, Nebraska, United States, 68131 Less <<
NCT00070486	Lung Cancer	Phase 2	Completed	-	-
NCT01174056	Lung Inflammation	Early Phase 1	Completed	-	United States, Missouri ... More >> Washington University / Barnes Jewish Hospital St. Louis, Missouri, United States, 63110 Less <<
NCT01805687	-		Completed	-	-
NCT00299065	Asthma	Phase 1 Phase 2	Completed	-	United States, California ... More >> Allergy & Asthma Specialist Medical Group Huntington Beach, California, United States, 92647 Allergy and Asthma Medical Group and Research Center San Diego, California, United States, 92123 United States, Colorado Colorado Allergy and Asthma Centers, PC Englewood, Colorado, United States, 80112 United States, Massachusetts Northeast Medical Research Associates North Dartmouth, Massachusetts, United States, 02747 United States, Minnesota Clinical Research Institute Minneapolis, Minnesota, United States, 55402 United States, Missouri The Clinical Research Center, L.L.C. St. Louis, Missouri, United States, 63141 United States, New Jersey Princeton Center for Clinical Research Skillman, New Jersey, United States, 08558 United States, Ohio Bernstein Clinical Research Center Cincinnati, Ohio, United States, 45231 United States, Oregon Allergy Associates Research Center Portland, Oregon, United States, 97213 United States, Texas Western Sky Medical Research El Paso, Texas, United States, 79902 Less <<
NCT00056004	Head and Neck Cancer ... More >> Lung Cancer Less <<	Phase 2	Completed	-	United States, Michigan ... More >> Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States, 48201-1379 Less <<
NCT00493974	Pulmonary Disease, Chronic Obs... More >>tructive Less <<	Phase 3	Terminated(Lack of feasibility... More >> due to low recruitment) Less <<	-	United States, Alabama ... More >> University of Alabama Lung Health Center Birmingham, Alabama, United States, 35249 Veteran's Administration Medical Center Birmingham, Alabama, United States, 35294 United States, California LA BioMed at Harbor, University of California Los Angeles, California, United States, 90502 University of California San Francisco-Airway Clinical Research Center San Francisco, California, United States, 94143 United States, Colorado Denver Health Medical Center Denver, Colorado, United States, 80204 National Jewish Medical and Research Center Denver, Colorado, United States, 80206 Veteran's Administration Medical Center Denver, Colorado, United States, 80220 United States, Maryland University of Maryland Hospital Baltimore, Maryland, United States, 21201 United States, Massachusetts Fallon Clinic Boston, Massachusetts, United States, 01605 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Veteran's Administration Medical Center Boston, Massachusetts, United States, 02132 United States, Michigan Veteran's Administration Medical Center Ann Arbor, Michigan, United States, 48105 University of Michigan Medical Center Ann Arbor, Michigan, United States, 48109 United States, Minnesota Veteran's Administration Medical Center Minneapolis, Minnesota, United States, 55417 HealthPartners Research Foundation Minneapolis, Minnesota, United States, 55440 Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Pennsylvania Temple University Lung Center Philadelphia, Pennsylvania, United States, 19140 University of Pittsburgh Emphysema Research Center Pittsburgh, Pennsylvania, United States, 15213 Less <<
NCT00262405	Idiopathic Pulmonary Fibrosis	Phase 2	Completed	-	United States, Michigan ... More >> University of Michigan Ann Arbor, Michigan, United States, 48109 Less <<
NCT00493974	-		Terminated(Lack of feasibility... More >> due to low recruitment) Less <<	-	-
NCT01021215	-		Completed	-	-
NCT00486343	Asthma	Phase 4	Terminated(Slower than anticip... More >>ated enrollment) Less <<	June 2008	United States, Massachusetts ... More >> Critical Therapeutics Lexington, Massachusetts, United States, 02421 Less <<
NCT00575861	Asthma	Phase 4	Completed	-	United States, California ... More >> Arthur F Gelb Medical Corporation Lakewood, California, United States, 90712 Less <<
NCT00098358	Acne Vulgaris	PHASE2	UNKNOWN	2025-05-05	Therapeutics Clinical Research... More >>, San Diego, California, 92123, United States\|MedaPhase, Inc., Newnan, Georgia, 30263, United States\|Dermatology Specialists, PSC, Louisville, Kentucky, 40202, United States\|Minnesota Clinical Study Center, Fridley, Minnesota, 55432, United States\|Academic Dermatology Associates, Albuquerque, New Mexico, 87106, United States\|SUNY Downstate Medical Center, Brooklyn, New York, 11203, United States\|Dermatology Associates of Rochester, Rochester, New York, 14623, United States\|Milton S. Hersey Medical Center, Hersey, Pennsylvania, 17033-0850, United States\|Rivergate Dermatology, Goodlettsville, Tennessee, 37072, United States\|DermResearch, Inc., Austin, Texas, 78759, United States\|J&S Studies, Inc., Bryan, Texas, 77802, United States\|Virginia Clinical Research, Inc., Norfolk, Virginia, 23507, United States Less <<
NCT00534625	Asthma	Phase 2	Completed	-	-
NCT01136941	Sickle Cell Disease	PHASE1	COMPLETED	2025-04-13	Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229, United States Less <<
NCT01021215	Tobacco Use Disorder	Phase 1 Phase 2	Completed	-	United States, New York ... More >> Weill Cornell Medical College in New York City, Cornell University New York, New York, United States, 10021 United States, Texas MD Anderson Cancer Center - Consortium Lead Organzation Houston, Texas, United States, 77030 Less <<
NCT01130688	Chronic Myelogenous Leukemia	PHASE1	TERMINATED	2025-12-14	University of Massachusetts Me... More >>dical School, Worcester, Massachusetts, 01655, United States Less <<
NCT02047149	Chronic Myelogenous Leukemia	Phase 1	Terminated(Low accrual)	-	United States, Massachusetts ... More >> University of Massachusetts Medical School Worcester, Massachusetts, United States, 01655 Less <<
NCT02348203	Current Every Day Smoker ... More >> Multiple Pulmonary Nodules Tobacco Smoking Tobacco Use Disorder Less <<	Phase 2	Recruiting	-	United States, Arizona ... More >> The University of Arizona Medical Center-University Campus Recruiting Tucson, Arizona, United States, 85724 Contact: Linda L. Garland 520-626-3434 lgarland@azcc.arizona.edu Principal Investigator: Linda L. Garland United States, California University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Jun Yan 530-752-5109 junyang@ucdavis.edu Principal Investigator: Jun Yan United States, Massachusetts Boston University School of Medicine Recruiting Boston, Massachusetts, United States, 02118 Contact: Avrum Spira 617-414-6960 aspira@bu.edu Principal Investigator: Avrum Spira Less <<

{[proInfo.proName]}

CAS No.: 111406-87-2

{[proInfo.proName]}

CAS No.: 111406-87-2

Alternative Products

Product Details of Zileuton

Safety of Zileuton

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed